Skip to main content
NVDA+0.55%AAPL-1.15%GOOGL-1.29%MSFT-0.75%AMZN-1.79%TSM-1.08%SPCX-2.05%META+0.76%AVGO-0.71%TSLA+0.05%SKHY-0.08%BRK-B-0.02%LLY+0.40%MU+0.51%JPM-1.41%WMT-0.34%AMD+1.69%V-0.41%XOM+1.82%JNJ-1.15%ASMLa-1.17%0700.HK+1.90%MA-0.61%INTC+0.93%ABBV-0.08%1398.HK-2.09%CSCO+0.45%CVX+1.55%BAC-0.41%ORCL-1.11%COST-1.27%KO-1.01%DELL+3.11%CAT-0.73%HSBA.L-1.91%0005.HK-3.21%PG+0.21%UNH-1.67%LRCX-2.49%AP2d-2.39%AMAT-1.33%1816.HK-0.46%3988.HK-2.13%NFLX-2.63%GE-2.59%MS-2.63%0857.HK+0.60%HD-1.49%PM-0.16%0939.HK-2.83%USDJPY+0.98%NZDUSD-0.93%CHFJPY+0.75%USDTHB+0.72%GBPJPY+0.67%GBPNZD+0.66%CADJPY+0.64%NZDCHF-0.62%NZDCAD-0.59%AUDUSD-0.58%EURUSD-0.49%EURJPY+0.47%EURNZD+0.45%AUDJPY+0.42%GBPTRY+0.41%NOKJPY+0.40%PLNJPY+0.38%AUDNZD+0.36%USDCAD+0.34%GBPHKD+0.32%USDCHF+0.31%NZDMXN-0.30%GBPMXN-0.28%GBPUSD-0.28%GBPAUD+0.28%SGDJPY+0.27%USDTRY+0.25%AUDCHF-0.25%AUDCAD-0.21%USDSEK+0.21%USDSGD+0.19%EURGBP-0.18%EURCAD-0.17%USDILS+0.16%EURCHF-0.16%EURSEK+0.15%EURSGD+0.14%CHFNOK-0.13%NZDSGD-0.13%EURCZK+0.12%EURAUD+0.10%GBPSGD+0.10%USDPLN+0.09%GBPZAR-0.09%AUDDKK-0.09%USDCNH+0.08%USDNOK+0.07%AUDNOK-0.07%GBPCAD+0.06%AUDSGD+0.06%NZDJPY+0.05%USDDKK+0.05%EURZAR-0.05%EURHKD-0.05%CADCHF-0.04%USDMXN+0.04%USDCOP-0.04%EURPLN+0.03%USDHKD+0.02%GBPCHF+0.01%USDZAR+0.01%CHFSGD-0.01%EURNOK+0.01%EURDKK-0.01%CHFSEK0.00%EURCNH0.00%USOIL+2.68%UKOIL+1.78%W1+1.52%XNGUSD+1.30%SUGAR-1.10%COFFEE-1.01%C1+0.87%COCOA-0.86%S1+0.82%HG1+0.39%XAUUSD-0.38%GAUUSD-0.38%BTCUSD-2.79%ETHUSD-4.17%USDTUSD-0.03%XRPUSD-2.53%SOLUSD-3.46%TRXUSDT-0.44%ZECUSDT-4.31%DOGEUSD-2.41%XMRUSDT+0.57%LINKUSD-2.70%XLMUSD+0.08%BCHUSDT-1.61%UNIUSD-3.53%LTCUSD-2.81%HBARUSDT-0.52%TONUSD+26.79%SUIUSD-2.90%TAOUSDT-3.72%AAVEUSD-2.66%DOTUSDT-2.31%ICPUSDT-7.29%ONDOUSDT-3.74%WLDUSDT-1.82%ARBUSDT+3.88%ATOMUSDT-1.85%JUPUSDT-4.72%INJUSDT-10.07%STXUSDT-3.49%FETUSDT-4.47%PYTHUSDT-4.62%TIAUSDT-6.43%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-2.68%GRTUSDT-4.45%WIFUSDT-5.33%POLUSDT+0.01%IOTAUSDT-5.93%AXSUSDT-3.52%FARTCOINUSDT-2.30%EOSUSDT-4.57%DYDXUSDT-6.40%ORDIUSDT-2.31%GALAUSDT-2.06%NOTUSDT-0.18%RONINUSDT-11.07%NVDA+0.55%AAPL-1.15%GOOGL-1.29%MSFT-0.75%AMZN-1.79%TSM-1.08%SPCX-2.05%META+0.76%AVGO-0.71%TSLA+0.05%SKHY-0.08%BRK-B-0.02%LLY+0.40%MU+0.51%JPM-1.41%WMT-0.34%AMD+1.69%V-0.41%XOM+1.82%JNJ-1.15%ASMLa-1.17%0700.HK+1.90%MA-0.61%INTC+0.93%ABBV-0.08%1398.HK-2.09%CSCO+0.45%CVX+1.55%BAC-0.41%ORCL-1.11%COST-1.27%KO-1.01%DELL+3.11%CAT-0.73%HSBA.L-1.91%0005.HK-3.21%PG+0.21%UNH-1.67%LRCX-2.49%AP2d-2.39%AMAT-1.33%1816.HK-0.46%3988.HK-2.13%NFLX-2.63%GE-2.59%MS-2.63%0857.HK+0.60%HD-1.49%PM-0.16%0939.HK-2.83%USDJPY+0.98%NZDUSD-0.93%CHFJPY+0.75%USDTHB+0.72%GBPJPY+0.67%GBPNZD+0.66%CADJPY+0.64%NZDCHF-0.62%NZDCAD-0.59%AUDUSD-0.58%EURUSD-0.49%EURJPY+0.47%EURNZD+0.45%AUDJPY+0.42%GBPTRY+0.41%NOKJPY+0.40%PLNJPY+0.38%AUDNZD+0.36%USDCAD+0.34%GBPHKD+0.32%USDCHF+0.31%NZDMXN-0.30%GBPMXN-0.28%GBPUSD-0.28%GBPAUD+0.28%SGDJPY+0.27%USDTRY+0.25%AUDCHF-0.25%AUDCAD-0.21%USDSEK+0.21%USDSGD+0.19%EURGBP-0.18%EURCAD-0.17%USDILS+0.16%EURCHF-0.16%EURSEK+0.15%EURSGD+0.14%CHFNOK-0.13%NZDSGD-0.13%EURCZK+0.12%EURAUD+0.10%GBPSGD+0.10%USDPLN+0.09%GBPZAR-0.09%AUDDKK-0.09%USDCNH+0.08%USDNOK+0.07%AUDNOK-0.07%GBPCAD+0.06%AUDSGD+0.06%NZDJPY+0.05%USDDKK+0.05%EURZAR-0.05%EURHKD-0.05%CADCHF-0.04%USDMXN+0.04%USDCOP-0.04%EURPLN+0.03%USDHKD+0.02%GBPCHF+0.01%USDZAR+0.01%CHFSGD-0.01%EURNOK+0.01%EURDKK-0.01%CHFSEK0.00%EURCNH0.00%USOIL+2.68%UKOIL+1.78%W1+1.52%XNGUSD+1.30%SUGAR-1.10%COFFEE-1.01%C1+0.87%COCOA-0.86%S1+0.82%HG1+0.39%XAUUSD-0.38%GAUUSD-0.38%BTCUSD-2.79%ETHUSD-4.17%USDTUSD-0.03%XRPUSD-2.53%SOLUSD-3.46%TRXUSDT-0.44%ZECUSDT-4.31%DOGEUSD-2.41%XMRUSDT+0.57%LINKUSD-2.70%XLMUSD+0.08%BCHUSDT-1.61%UNIUSD-3.53%LTCUSD-2.81%HBARUSDT-0.52%TONUSD+26.79%SUIUSD-2.90%TAOUSDT-3.72%AAVEUSD-2.66%DOTUSDT-2.31%ICPUSDT-7.29%ONDOUSDT-3.74%WLDUSDT-1.82%ARBUSDT+3.88%ATOMUSDT-1.85%JUPUSDT-4.72%INJUSDT-10.07%STXUSDT-3.49%FETUSDT-4.47%PYTHUSDT-4.62%TIAUSDT-6.43%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-2.68%GRTUSDT-4.45%WIFUSDT-5.33%POLUSDT+0.01%IOTAUSDT-5.93%AXSUSDT-3.52%FARTCOINUSDT-2.30%EOSUSDT-4.57%DYDXUSDT-6.40%ORDIUSDT-2.31%GALAUSDT-2.06%NOTUSDT-0.18%RONINUSDT-11.07%
AL

Alkermes plc (ALKS)

NASDAQ • Healthcare

$45.83
-$0.14 (-0.3%)
Market open

Last close at September 14, 2026 at 20:00 UTC

Open$46.6
Previous Close$45.83
Day Range$45.66 - $46.6
Avg. Volume (3M)1.3M
Market Cap$7.6B
P/E Ratio114.6
52 Week Range
$26.5$55.67
Next EarningsIn 43 daysOct 28, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$496M100%
Gross Profitminus cost of goods$397.8M80%
Operating Incomeminus R&D and overhead$18.3M4%
Net Incomeminus taxes and the rest$501K0%

Fundamentals & Financials

Revenue (TTM)
$1.6B
Net Income (TTM)
$66.1M
EPS (TTM)
$0.4
ROA (TTM)
1.51%
Current Ratio
2.3
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-20.9%Q1 2026$0.34
+29.8%Q2 2026-$0.4
+2650.1%Q3 2026$0.7
Next

Oct 28

in 43 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +2650.1%

Alkermes topped consensus revenue expectations in the second fiscal quarter of 2026, with results reported July 28, 2026, as revenue rose 27% to about $496.0 million (up from roughly $390.7 million a year ago) and came in at $496.0 million versus a $457.4 million estimate, +8.4% (topped). Adjusted EPS was $0.70, while profitability included gross profit of about $397.9 million with gross margin near 80% and operating income of roughly $18.4 million, translating to an operating margin of around 4%. The company generated operating cash flow of about $145.2 million during the quarter. For the next period, consensus calls for EPS of $-0.08 on revenue of $463.9 million.

View full earnings history

About Alkermes plc

Alkermes plc is a biotechnology company listed on NASDAQ as ALKS that develops and commercializes central nervous system medicines and related drug-delivery capabilities. Its portfolio spans schizophrenia, addiction, bipolar disorder, and sleep disorders, and it generated $1.5 billion of revenue in FY2025.

Name
Alkermes plc
CEO
Blair Jackson
Website
www.alkermes.com
Industry
Healthcare
Year Founded
1987
Employees
2,050

Today's Snapshot

AI-generated

The session opened with ALKS slightly lower at 45.73, while its sector was flat.

Trading Volume

Below 10d avg (1.2M)

194.6K

vs S&P 500 Today

Underperforming Market

-1.52%

Updated: September 15, 2026 at 14:52 UTC

Technical Indicators

1 Buy2 Neutral5 Sell
ALKS is trading near 45.18 and technicals skew negative as momentum measures show weakness, with a low RSI around 34 and a negative MACD level indicating bearish momentum while the CCI is notably below zero. The stock trades beneath short and intermediate moving averages even though it remains above the 200-day band, which highlights near-term pressure against a longer-term support level. ADX is muted, suggesting a lack of strong trending conviction, and volatility is moderate with an ATR around 1.39 while on-balance volume is weak. Technical takeaway: Sell — short-term momentum and moving average alignment favor downside pressure.
All signals
  • EMA (5 indicators)$39.72 - $47.67
    Sell
  • RSI (14)34.17
    Neutral
  • Stochastic %K (14, 3, 3)20.97
    Neutral
  • MACD Level (12, 26)-1.07
    Sell

Peers & Related Assets

ARWRArrowhead Pharmaceuticals, Inc.
$80.67-2.6%
PTGXProtagonist Therapeutics, Inc.
$147.78-0.3%
KYMRKymera Therapeutics, Inc.
$114.63-0.3%
PCVXVaxcyte, Inc.
$59.54+0.1%
TGTXTG Therapeutics, Inc.
$54+0.2%
PTCTPTC Therapeutics, Inc.
$66.48+0.6%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.